CL2019000568A1 - Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos - Google Patents

Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos

Info

Publication number
CL2019000568A1
CL2019000568A1 CL2019000568A CL2019000568A CL2019000568A1 CL 2019000568 A1 CL2019000568 A1 CL 2019000568A1 CL 2019000568 A CL2019000568 A CL 2019000568A CL 2019000568 A CL2019000568 A CL 2019000568A CL 2019000568 A1 CL2019000568 A1 CL 2019000568A1
Authority
CL
Chile
Prior art keywords
methods
compounds
azetidin
triazolo
pyridinyl
Prior art date
Application number
CL2019000568A
Other languages
English (en)
Spanish (es)
Inventor
Simon Charles Goodacre
Yun-Xing Cheng
Mark Zak
F Anthony Romero
Limin Cheng
Rongbao Hua
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2019000568A1 publication Critical patent/CL2019000568A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2019000568A 2016-09-06 2019-03-06 Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos CL2019000568A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2016098215 2016-09-06

Publications (1)

Publication Number Publication Date
CL2019000568A1 true CL2019000568A1 (es) 2019-07-12

Family

ID=59761965

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000568A CL2019000568A1 (es) 2016-09-06 2019-03-06 Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos

Country Status (19)

Country Link
US (3) US20190202822A1 (OSRAM)
EP (2) EP3510030B1 (OSRAM)
JP (1) JP7050761B2 (OSRAM)
KR (1) KR20190045302A (OSRAM)
CN (1) CN109890817B (OSRAM)
AU (1) AU2017324281A1 (OSRAM)
BR (1) BR112019004486A2 (OSRAM)
CA (1) CA3035712A1 (OSRAM)
CL (1) CL2019000568A1 (OSRAM)
CO (1) CO2019002171A2 (OSRAM)
CR (1) CR20190118A (OSRAM)
IL (1) IL265153A (OSRAM)
MA (1) MA46176A (OSRAM)
MX (1) MX2019002627A (OSRAM)
PE (1) PE20190632A1 (OSRAM)
PH (1) PH12019500478A1 (OSRAM)
RU (1) RU2019109570A (OSRAM)
SG (1) SG11201901954XA (OSRAM)
WO (1) WO2018046409A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7716993B2 (ja) * 2019-06-18 2025-08-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｊａｋキナーゼのピラゾロピリミジンアリールエーテル阻害剤及びその使用
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024148184A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Compounds and processes for the preparation of jak inhibitors
AU2024206079A1 (en) * 2023-01-04 2025-07-10 Alcon Inc. Polymorphs of a jak1/tyk2 inhibitor and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO1997002289A1 (en) 1995-07-06 1997-01-23 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
CA2470813A1 (en) 2001-12-20 2003-07-03 Bayer Healthcare Ag 1,4-dihydro-1,4-diphenylpyridine derivatives
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
EP2288260A4 (en) 2008-06-20 2013-10-23 Genentech Inc TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
CA2763900A1 (en) 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
UA117830C2 (uk) * 2013-05-17 2018-10-10 Інсайт Корпорейшн Похідні біпіразолу як інгібітори jak
SG11201601707PA (en) * 2013-09-05 2016-04-28 Hoffmann La Roche Triazolopyridine compounds, compositions and methods of use thereof
JP2018507236A (ja) * 2015-03-04 2018-03-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリアゾロピリジン化合物及びその使用法

Also Published As

Publication number Publication date
CR20190118A (es) 2019-04-30
JP2019526593A (ja) 2019-09-19
EP3510030B1 (en) 2023-03-22
RU2019109570A (ru) 2020-10-08
AU2017324281A1 (en) 2019-03-21
US20230242530A1 (en) 2023-08-03
EP4198036A1 (en) 2023-06-21
KR20190045302A (ko) 2019-05-02
MX2019002627A (es) 2019-10-30
US20190202822A1 (en) 2019-07-04
US20200270248A1 (en) 2020-08-27
IL265153A (en) 2019-05-30
SG11201901954XA (en) 2019-04-29
CA3035712A1 (en) 2018-03-15
BR112019004486A2 (pt) 2019-05-28
WO2018046409A1 (en) 2018-03-15
MA46176A (fr) 2019-07-17
EP3510030A1 (en) 2019-07-17
PH12019500478A1 (en) 2019-12-02
CN109890817B (zh) 2022-06-17
PE20190632A1 (es) 2019-04-26
RU2019109570A3 (OSRAM) 2020-10-08
CO2019002171A2 (es) 2019-05-21
CN109890817A (zh) 2019-06-14
JP7050761B2 (ja) 2022-04-08

Similar Documents

Publication Publication Date Title
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
MX384948B (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos.
EA201591255A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
EA201791066A1 (ru) Твердые формы ингибитора ask1
MX2016010571A (es) Pirazolil-ureas como inhibidores de quinasas.
SI3523302T1 (sl) Substituirane spojine pirazolo(1,5-A)piridina kot inhibitorji ret kinaze
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX372939B (es) Inhibidores de cinasa janus 1 (jak1) para el tratamiento de sindromes mielodisplasicos.
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
PH12017501032A1 (en) 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS
SI3880676T1 (sl) Derivati 2,3-dihidro-1h-pirolo(3,4-c)piridin-1-ona kot zaviralci hpk1 za zdravljenje raka
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
BR112018005851A2 (pt) derivados de pirrolo[2,3-d]pirimidina como inibidores de dyrk1 / clk1 duais
IL254224B (en) History of 5-alkyl-7-(piperidinyl/morpholinyl)-[4,2,1]triazolo[5,1-a]pyrimidine for use in medical treatment
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
CL2019000568A1 (es) Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos
MX2018008362A (es) Derivados de quinolin-2-ona.
CL2016000496A1 (es) Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
EA201790603A1 (ru) Ингибиторы гистондеметилазы
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
IL290419A (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
PH12017500159A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
CR20160539A (es) Compuestos de 2-cloro-2difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos